Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket studyFunda Meric‐Bernstam, John D. Hainsworth, Charles Swanton et al.|The Lancet Oncology|2019Cited by 564
Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension studyMartin Reck, Stephen V. Liu, Rafał Dziadziuszko et al.|Lung Cancer|2024Cited by 66
Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and NeckRobert I. Haddad, Deborah Jean Lee Wong, Jérôme Fayette et al.|JAMA|2025Cited by 42